Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure (NCT00400985), a na na study. The primary outcome is Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion..

2. Clinical Question

The study's brief summary describes a prospective evaluation of sensitivity and positive predictive value for OptiVol Fluid Trends data. These are distinct measures of prediction: sensitivity concerns how often a prediction system signals for events that occur, while positive predictive value concerns how often a signal is followed by an event. Neither measure is reported as a result in the registry record.

The question is about prediction and monitoring in an implanted-device setting, rather than a treatment comparison. Since the record does not give a control arm or report a primary-outcome analysis, it does not establish a comparative effect of OptiVol monitoring. The registry also describes an aim to define clinical guidelines for subject therapy management, but the guideline results are not reported in the registry record.

3. Trial Design

The registry describes SENSE-HF as a prospective, observational, international, multicenter study. Its status is completed. The recorded study start is 2005-01, and primary completion is recorded as 2009-08. Enrollment is 501. The condition listed is congestive heart failure.

The design is marked single group, with allocation listed as not applicable. All enrolled subjects were implanted with a device. Device diagnostics are described as audible and as turned on or off; the registry does not describe a separate, randomized control group. The study therefore should not be read as a head-to-head comparison of two assigned treatment strategies. The exclusion of an arm-to-arm control comparison is consistent with the registry's design description.

Masking is recorded as double. The registry record does not explain which people were masked, what information was concealed, or how masking operated in this observational setting. The study phase is listed as not applicable. The intervention is an implantable device used to monitor intrathoracic impedance through the OptiVol diagnostic tool.

The primary outcome is a number of hospitalizations, with a timeframe beginning 34 days post device implant and extending to 6 months. The record lists one outcome measure and zero analyses. It does not report details of the statistical analysis used for the primary outcome. In particular, the registry record does not report a protocol-based sample-size justification or a statistical analysis plan.

The study's stated aim was to evaluate prediction of heart-failure-related hospitalization and health-care use associated with signs or symptoms of pulmonary congestion, as well as to define OptiVol clinical guidelines for subject therapy management. Those aims describe the intended work; they should not be mistaken for reported findings. Numerical outcome findings and prediction-performance estimates are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion., measured over 34 days post device implant to 6 months.

The primary endpoint is titled as prediction by OptiVol of heart-failure-related hospitalizations with signs or symptoms of pulmonary congestion. Its measurement parameter is a number, and its unit is hospitalization. The recorded timeframe is 34 days post device implant to 6 months.

A count endpoint records how many qualifying events occur under the endpoint definition. It differs from a binary endpoint that records whether each participant did or did not experience an event, and it also differs from a time-to-event endpoint that measures how long it takes for an event to occur. In general, event counts can describe repeated events, but the registry record does not specify whether repeat hospitalizations were counted separately, how events were adjudicated, or how the count was attributed to participants.

Hospitalization is relevant to the stated prediction question because the study aimed to assess whether OptiVol Fluid Trends data could predict heart-failure-related hospitalizations associated with signs or symptoms of pulmonary congestion. A prediction system's performance is not established by the endpoint definition alone: it requires reported event data and a specified analysis connecting predictions to observed events. Sensitivity and positive predictive value are named as study aims, but their definitions as operationalized in the study are not reported in the registry record.

The registry supplies no numerical result for the primary count endpoint, no confidence interval, and no analysis details. Accordingly, the endpoint's definition can be described, but the number of qualifying hospitalizations and the precision of any estimated prediction performance cannot be assessed from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies a single-group observational study and a count outcome. These design and measurement features matter when interpreting what statistical methods could answer the study question. The methods actually used for the primary analysis are not reported in the registry record, so general statistical explanations must not be mistaken for a description of the study's analysis.

What does a count endpoint represent?

A count is a non-negative tally of events. For a hospitalization outcome, interpretation depends on which admissions qualify, whether multiple admissions for one participant are counted separately, and how observation time is defined. The registry names heart-failure-related hospitalization with signs or symptoms of pulmonary congestion and gives a timeframe of 34 days post device implant to 6 months. It does not further report event-adjudication rules or whether repeat events were included. These details affect what the count represents and how it can be compared or modeled.

In general, count data are often analyzed using models that relate the expected event count to predictors. A Poisson model is one familiar approach, but it assumes that the variability is linked to the mean in a particular way. If the data vary more than that model allows, over-dispersion can make conventional uncertainty estimates too small. Methods that account for extra variability may then be appropriate. This is general statistical context only: the registry does not identify a Poisson model, an over-dispersion assessment, or any alternative method for this endpoint.

How does prediction differ from a treatment comparison?

A treatment comparison estimates a contrast between groups receiving different assigned strategies. A prediction analysis asks how well information available at a specified time anticipates a later outcome. The registry describes a single-group observational study, with allocation marked not applicable, rather than a randomized comparison. Its summary names sensitivity and positive predictive value as prediction objectives. In general, sensitivity evaluates the proportion of events identified by a prediction signal, while positive predictive value evaluates the proportion of signals followed by the event of interest. Both require a clear definition of the signal, the event, and the observation window. The registry record does not report the operational definitions or numerical estimates.

Prediction measures can be affected by how common an event is in the population being monitored and by how a signal threshold is chosen. Sensitivity and positive predictive value describe different aspects of performance; one cannot be substituted for the other. The registry does not report a threshold, classification rule, or performance analysis, so neither measure can be reconstructed from the record's enrollment and safety entries.

What does statistical uncertainty add?

An estimate describes the observed result, while an uncertainty measure communicates how much statistical imprecision surrounds it under the analysis assumptions. A confidence interval is a commonly used uncertainty measure. For prediction performance, a confidence interval would help show the precision of an estimate such as sensitivity or positive predictive value. No such estimates or intervals are reported for the primary endpoint in the registry record. Without them, it is not possible to judge whether any estimated performance is precise or highly uncertain.

Hypothesis tests and p-values address questions defined by a statistical model and analysis plan. They do not, by themselves, measure the size or practical importance of an effect. The registry record lists zero analyses and does not report a primary-outcome test or a statistical plan. No significance conclusion can therefore be drawn from the posted results.

How should planning calculations be understood?

General sample-size planning calculations estimate the amount of information needed under assumptions about an effect, allocation, significance level, and analysis method. The planning description associated with this study uses a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. It specifies that time-to-event displays give total events and other displays give participants per arm.

Those assumptions describe planning illustrations, not the design recorded for SENSE-HF. The actual registry design is single group, not a two-arm randomized comparison. A hypothetical equal-allocation calculation should not be interpreted as an account of how participants were assigned in this study. Nor is a planning calculation evidence of observed power: power is a design concept, and post-study results should be interpreted through estimates and uncertainty, not by treating a planning number as a result. The registry record does not report its own sample-size justification, and the observed primary outcome effect needed to evaluate the planning basis is not reported.

For time-to-event outcomes, a general planning method may focus on a required number of events; for other outcomes, it may express a target number of participants per arm. Those conventions do not change the actual endpoint, which the registry describes as a number of hospitalizations. The statistical model used for that count, the handling of follow-up time, the analysis population, and the primary analysis are not reported in the registry record.

Because the available record lacks an endpoint result and analysis specification, no method can be endorsed as the method used in this study, and no recalculation of the primary analysis is possible. Any general method discussion is explanatory rather than a claim about the investigators' procedure.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists one outcome measure and zero analyses. This is not enough to establish how many outcomes, time points, or prediction measures were examined in the full study, or whether a multiplicity strategy was planned. The record does not report an adjustment for multiple comparisons, a hierarchy of tests, or a prespecified approach to selecting among analyses. These details are not reported in the registry record.

Multiplicity matters when several statistical questions are tested: the chance of at least one apparently notable result can increase as the number of tests grows. In general, a prespecified testing strategy can help readers distinguish primary conclusions from exploratory findings. The registry's single listed primary measure does not establish that no additional analyses were conducted, particularly because no analysis details are recorded.

Missing-data procedures are also not reported in the registry record. The enrollment figure does not say how many participants had complete follow-up for the primary endpoint, whether any observations were censored or unavailable, or how missing information was handled. The outcome analysis population and rules for inclusion are not reported. No assumptions about complete follow-up, imputation, or exclusion should be inferred.

The record does not report interim analyses or stopping rules. Their absence from the record should not be interpreted as evidence that none occurred. It also does not provide a protocol-based statistical plan with which to compare the posted results. These omissions limit assessment of whether analyses were planned in advance and how selectively reported results might be.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0.9% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: hf related hospitalization (8.4%).

The registry's safety listing gives Group 1 as having 501 at risk in the serious adverse-event entry and 501 at risk in the other adverse-event entry. It lists 42 under serious adverse events and 52 under other adverse events. These are registry entries; the record does not provide further detail about event-level definitions, whether individuals could contribute to both categories, or the observation period for these entries.

Heart-failure-related hospitalization is listed as a leading serious-event term with 8.4%. This safety listing should not automatically be treated as the primary outcome result. The primary endpoint is defined separately as the number of heart-failure-related hospitalizations with signs or symptoms of pulmonary congestion over 34 days post device implant to 6 months. The registry does not explain whether the safety term and primary endpoint use identical definitions, populations, or follow-up rules.

The deaths field has no reported value in the registry record. The adverse-event entries alone do not establish a comparative safety effect because the design has no like-for-like control group. They also do not provide the context needed to interpret event timing or relationship to the device. These figures describe what the registry records and should not be used as a treatment recommendation.

12. What the Result Does, and Does Not, Mean

The record describes a prospective observational evaluation of OptiVol Fluid Trends data, focused on predicting heart-failure-related hospitalizations associated with signs or symptoms of pulmonary congestion. It specifies an implanted monitoring device, a single-group design, and a primary outcome expressed as a hospitalization count. These features clarify the question the study set out to address.

However, the registry does not report the primary outcome count, sensitivity, positive predictive value, or a statistical analysis of prediction performance. It also does not provide confidence intervals or other precision measures for those outcomes. As a result, the record cannot establish how accurately the device data predicted hospitalization, how precise any estimate was, or whether any prediction measure met a particular standard.

The observational, single-group design also differs from a randomized comparison of monitoring strategies. It cannot, on the information recorded, isolate a comparative effect of OptiVol monitoring against a control group. A predictive association, even if reported, would be a different claim from evidence that using the monitoring tool changes clinical outcomes. The registry's summary mentions an aim to define clinical guidelines, but guideline conclusions are not reported in the registry record.

Enrollment and adverse-event information do not fill the gap in primary-outcome reporting. The listed safety figures are not a replacement for a defined prediction analysis, and the record does not establish that their endpoint definitions match the primary measure. The completed status indicates that the study is recorded as completed, not that the registry includes all results needed to answer its stated questions.

The defensible interpretation is therefore limited: the registry documents a study intended to evaluate device-based prediction and records some design and safety information, but it does not report the main quantitative results needed to judge predictive performance or its statistical precision.

13. Why This Trial Matters Statistically

This study raises an important statistical distinction between monitoring, prediction, and treatment comparison. OptiVol was used to monitor intrathoracic impedance, while the stated study aims concerned prediction of hospitalization and estimation of sensitivity and positive predictive value. Those are prediction questions; they are not equivalent to demonstrating that monitoring itself changes outcomes.

The design record makes this distinction especially relevant. The study is described as prospective and observational, with a single-group model and no like-for-like control comparison. Such a design can be directed at describing the relationship between a monitoring signal and subsequent events, but a comparative treatment-effect question requires an appropriate comparison. The registry does not report the analysis needed to evaluate the prediction question.

The endpoint also illustrates why clear measurement definitions matter. A hospitalization count depends on which events qualify, the period in which they are counted, and how repeated events are handled. The registry names a specific clinical event and timeframe but does not report additional event rules or numerical results. Without these, readers cannot assess how the endpoint was operationalized or how its results relate to the stated performance measures.

Finally, the record demonstrates the importance of complete statistical reporting. Enrollment, study status, and adverse-event entries are not substitutes for an outcome estimate, its uncertainty, and a description of the analysis population and method. For researchers, the case underscores why prospective prediction studies need transparent definitions of signals and outcomes, prespecified analysis methods, and results that include precision. The registry entry records the aims and broad structure, but its missing primary analysis prevents a quantitative assessment of whether those aims were achieved.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation is the absence of a reported numerical result for the named hospitalization-count endpoint. The registry record does not give an event count, an estimate of prediction performance, a confidence interval, or a statistical test. Consequently, neither the magnitude nor the precision of the primary result can be assessed.

The outcome definition is brief. Although it specifies heart-failure-related hospitalization with signs or symptoms of pulmonary congestion and a timeframe of 34 days post device implant to 6 months, the record does not report event-adjudication criteria, handling of repeated hospitalizations, or details of follow-up. Those omissions restrict interpretation of what the endpoint count would represent.

The design is single group and observational, with no like-for-like control comparison. The record does not explain which people were masked despite listing double masking, or describe how the audible device diagnostics being on or off related to study procedures. Allocation is listed as not applicable, so no randomized allocation process can be inferred.

The registry lists enrollment but does not report the primary analysis population, completeness of outcome follow-up, missing-data handling, or the statistical method. It also does not report a multiplicity plan, interim analyses, or a study-specific sample-size justification. The safety entries do not resolve these gaps, and the record does not explain their relationship to the primary endpoint. These limitations are specific to the information recorded for this study and prevent a full statistical appraisal of the intended prediction analysis.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure — NCT00400985.
• Registry record last updated 2025-07-02; status last verified 2018-01.
• Results first posted 2018-10-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes SENSE-HF as a completed, prospective, observational, international multicenter study of OptiVol monitoring in people with congestive heart failure. Enrollment is 501. All enrolled subjects were implanted with a device, and the design is listed as single group with allocation not applicable.

The primary endpoint is a number of heart-failure-related hospitalizations with signs or symptoms of pulmonary congestion, over 34 days post device implant to 6 months. The study summary identifies sensitivity and positive predictive value as objectives. The registry lists one outcome measure and zero analyses, and does not report numerical results for the primary outcome or prediction measures.

Safety entries list 42 serious adverse events and 52 other adverse events, with 501 at risk in each entry; heart-failure-related hospitalization is listed as a leading serious-event term at 8.4%. The deaths field has no reported value. The available record supports description of the design and objectives, but not a quantitative conclusion about predictive performance.